Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

By G. Glinsky, O. Berezovska, A. Glinskii. Journal of Clinical Investigation, 2005

966 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/46716ef526d24b34b00bb7470ffa53766982b5f7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Inferring Pathway Activity toward Precise Disease Classification (2008, background): “Alternative approaches engineer normal cells to activate pre-selected oncogenic pathways to determine gene signatures which can distinguish tumor characteristics [20,25].”
Common markers of proliferation (2006, background): “This pattern was associated with poor outcomes in patients with a variety of tumour type”
Cancer as a metabolic disease (2010, background): “Fusions among metastatic myeloid cells at the primary tumor site could, through reprogramming strategies, also produce functional epithelial cells at secondary sites potentially simulating the histological characteristics of the original tissue of origin [200,211,212].”
Cancer stem cells: an old idea--a paradigm shift. (2006, background): “was associated with a poor prognosis for 10 different types of human malignancies (52).”
Radial glia cells are candidate stem cells of ependymoma. (2005, background): “One of the most immediate clinical applications of cancer stem cell biology is the generation of prognostic tools (Glinsky et al., 2005; Singh et al., 2003).”
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. (2011, background): “This notion has spread from studies that used expression signatures derived from tumor-initiating cells (Glinsky et al., 2005).”
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy (2013, background): “The performance of GC was compared to that of previously published gene signatures [11–13,15,16,18–24,28–30] and individual genomic markers associated with prostate cancer progression including CHGA [43], DAB2IP [44], GOLPH2 [45], PAP [46], ETV1 and ERG [47], KI-67 [48], PSA [49], PSCA [50], PSMA [5”
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. (2006, background): “The clinical importance of this is highlighted by a recent report demonstrating a strong correlation between the expression of an 11-gene Bmi-1 stem cell signature and poor prognosis in patients with a wide variety of malignancies (36).”
Molecular definition of breast tumor heterogeneity. (2007, background): “…of an 11-gene, BMI1-driven stem cell gene signature in a large collection of gene expression data from several different tumor types determined that this signature is a powerful predictor of short diseasefree and overall survival and the risk of distant metastases (Glinsky et al., 2005).”
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature (2009, positive): “A link between CSC and metastasis was first suggested with the identification of stem cell genes in an 11-gene signature generated using comparative profiles of metastatic and primary tumors in a transgenic mouse model of prostate cancer and in cancer patients (49).”
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome (2011, background): “These include signatures of stem cells [13–15], aneuploidy [16], wound healing [17,18], hypoxia [19,20], stromal component [21], epithelialmesenchymal transition [22–24]; of mutations in TP53 [25], ALK5 [26]; of loss of PTEN [27]; of perturbations of E2F1 [28], bromodomain 4 [29], mir31 targets [30]”